Moshit Lindzen
Rehovot, M 76100, Israel
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Sensitizing Immune-Refractory Ovarian Tumors via p53 Mutation-Tailored Immunotherapy.
Journal: bioRxiv : the preprint server for biology
Published: July 16, 2025
Re-epithelialization of cancer cells increases autophagy and DNA damage: Implications for breast cancer dormancy and relapse.
Journal: Science signaling
Published: April 22, 2025
Tuft cells and fibroblasts promote thymus regeneration through ILC2-mediated type 2 immune response.
Tuft cells and fibroblasts promote thymus regeneration through ILC2-mediated type 2 immune response.
Journal: Science immunology
Published: January 12, 2024
A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib.
Journal: Cell reports. Medicine
Published: December 18, 2023
L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab.
Journal: Cell reports. Medicine
Published: September 07, 2022
Computational optimization of antibody humanness and stability by systematic energy-based ranking.
Journal: Nature biomedical engineering
Published: August 18, 2022
Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies.
Journal: Frontiers in oncology
Published: May 23, 2022
Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors.
Journal: Cell reports
Published: March 11, 2021
Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors.
Journal: Cancer research
Published: October 22, 2020
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.
Journal: Cancers
Published: July 23, 2020
Last Updated: 09/26/2026